BPC-157 Capsules

BPC-157, or Body Protection Compound-157, is a synthetic peptide consisting of 15 amino acids. It is derived from a naturally occurring protein found in human gastric juice. BPC-157 has been studied for its potential to promote tissue repair, reduce inflammation, and support overall healing processes.

BPC-157 Peptide Research

BPC-157 and Wound Healing

The natural role of BPC-157 in the gastrointestinal (GI) tract is to maintain the integrity of the mucosal barrier, protecting underlying tissues from harmful agents such as gastric acid, bile, and other digestive compounds. This function is partly mediated by the recruitment of fibroblasts. BPC-157 exhibits a dose-dependent effect on fibroblast proliferation and migration both in culture and in vivo. Fibroblasts are essential for wound healing, as they lay down extracellular matrix proteins including collagen, fibrin, and elastin.

Vascular Growth and Collateralization

BPC-157 is a potent angiogenic factor that enhances the proliferation and growth of endothelial cells—the cells lining blood vessels. Studies in rats demonstrate that the peptide significantly accelerates collateral blood vessel growth under ischemic conditions. While this effect has been mostly observed in the GI tract, evidence also supports similar benefits in cardiovascular, neurological, and muscular tissues. 

This suggests potential therapeutic applications in stroke and heart attack, as well as a model for promoting healing after ischemic injury. Research in chicken embryos suggests that BPC-157 promotes vascular growth via stimulation of VEGFR2, a receptor involved in nitric oxide signaling, which plays a critical role in endothelial cell function and longevity.

Cell culture studies have shown "vascular running," the growth of new vessels toward injury sites or around occlusions to restore blood flow and preserve cell function. This feature of BPC-157 raises the possibility of developing oral treatments for slow-growing arterial occlusions seen in conditions such as atherosclerosis. Such advances could reduce the need for surgical interventions like stenting or coronary artery bypass grafting.

BPC-157 and Tendon Healing

Given its roles in fibroblast recruitment and angiogenesis, BPC-157 has shown promising results in animal models of tendon, ligament, bone, and connective tissue injuries. These injuries heal slowly largely due to poor blood supply, which limits fibroblast and healing cell recruitment. Both in vitro and in vivo research in rat tendons indicates that BPC-157 promotes collateralization and increases fibroblast density in injured tendons, ligaments, and bones. This peptide outperforms growth factors such as bFGF, EGF, and VEGF in these contexts. Experiments using FITC-phalloidin staining reveal that BPC-157 strongly stimulates F-actin formation in fibroblasts, which is crucial for cell structure and migration. Western blot analysis shows increased phosphorylation of paxillin and FAK proteins, key regulators in the cell migration pathway.

Antioxidant Properties

Rat studies demonstrate that BPC-157 neutralizes oxidative stress markers like nitric oxide and malondialdehyde (MDA), confirming its role as a powerful antioxidant. Further research shows it reduces reactive oxygen species production in the GI tract. Modified Lactococcus lactis bacteria engineered to deliver BPC-157 dramatically increase peptide levels in cell cultures.

BPC-157 and Drug Side Effects

Side effects often limit the use of pharmaceuticals; for example, NSAIDs like ibuprofen increase risks of gastric bleeding and heart attack when used long-term. The ability to mitigate side effects while preserving therapeutic benefits is a key research goal. BPC-157 counters side effects from NSAIDs, psychiatric medications, and various heart drugs. Besides protecting the GI tract, BPC-157 also shields the brain, heart, and other tissues from adverse drug effects. In rats, it prevents QTc prolongation—a heart rhythm condition caused by some diabetes and psychiatric drugs—and reduces side effects such as catalepsy and somatosensory disturbances induced by psychiatric medications. These benefits may improve patient adherence to psychiatric treatments, which are often abandoned due to severe side effects.

BPC-157 and Bees

Colony Collapse Disorder (CCD) causes rapid decline and loss of honey bee colonies, partly due to infection by the fungus Nosema ceranae in bee guts. Supplementing honey bee diets with BPC-157 reduces fungal damage and improves hive survival rates. These field trials represent the first significant oral treatment to mitigate CCD’s impact on vital pollinators for many food crops.

BPC-157 is actively studied in various cell culture and animal models. It shows significant promise both as a therapeutic agent for wound healing and vascular growth regulation and as a tool to better understand angiogenesis—a process vital to healing, growth, cancer development, and embryogenesis.

BPC-157 exhibits minimal side effects, with moderate oral and excellent subcutaneous bioavailability in mice. Mouse dosages do not directly scale to humans. BPC-157 sold by Peptide Sciences is for educational and scientific research only and is not intended for human consumption. Purchases are restricted to licensed researchers.

Research Applications

BPC-157 is primarily utilized in scientific studies focusing on:

• Tissue Repair: Investigating its role in accelerating the healing of wounds, tendons, ligaments, and muscles.
• Gastrointestinal Health: Exploring its potential to support gut health and protect against ulcers.
• Inflammation Reduction: Assessing its effects on reducing inflammation in various tissues
• Neuroprotection: Studying its potential to protect nerve cells and support neurological health.

Product Specifications

• Form: Capsules containing lyophilized (freeze-dried) BPC-157 powder.
• Dosage: Each capsule contains 250mcg of BPC-157.
• Quantity: Each bottle contains 60 capsules.
• Purity: Typically ≥99%, ensuring high-quality material for research purposes.
• Packaging: Sealed bottles to maintain product integrity.
• Storage: Store in a cool, dry place away from direct sunlight.

Safety and Handling

BPC-157 is intended strictly for laboratory research and is not approved for human consumption. Handle with care, following appropriate safety protocols. Ensure proper storage conditions to maintain the integrity and efficacy of the compound.

Referenced Citations

• T. Huang et al., “Body protective compound-157 enhances alkali-burn wound healing in vivo and promotes proliferation, migration, and angiogenesis in vitro,” Drug Des. Devel. Ther., vol. 9, pp. 2485–2499, 2015. 
• D. Drmic et al., “Counteraction of perforated cecum lesions in rats: Effects of pentadecapeptide BPC 157, L-NAME and L-arginine,” World J. Gastroenterol., vol. 24, no. 48, pp. 5462–5476, Dec. 2018. 
• F. Amic et al., “Bypassing major venous occlusion and duodenal lesions in rats, and therapy with the stable gastric pentadecapeptide BPC 157, L-NAME and L-arginine,” World J. Gastroenterol., vol. 24, no. 47, pp. 5366–5378, Dec. 2018. 
• A. Duzel et al., “Stable gastric pentadecapeptide BPC 157 in the treatment of colitis and ischemia and reperfusion in rats: New insights,” World J. Gastroenterol., vol. 23, no. 48, pp. 8465–8488, Dec. 2017. 
• J. Vukojević et al., “Rat inferior caval vein (ICV) ligature and particular new insights with the stable gastric pentadecapeptide BPC 157,” Vascul. Pharmacol., vol. 106, pp. 54–66, 2018. 
• D. Drmic et al., “Celecoxib-induced gastrointestinal, liver and brain lesions in rats, counteraction by BPC 157 or L-arginine, aggravation by L-NAME,” World J. Gastroenterol., vol. 23, no. 29, pp. 5304–5312, Aug. 2017. 
• M.-J. Hsieh et al., “Therapeutic potential of pro-angiogenic BPC 157 is associated with VEGFR2 activation and up-regulation,” J. Mol. Med., vol. 95, no. 3, pp. 323–333, 2017. 
• Z. Grabarevic et al., “The influence of BPC 157 on nitric oxide agonist and antagonist induced lesions in broiler chicks,” J. Physiol. Paris, vol. 91, no. 3–5, pp. 139–149, Oct. 1997. 
• P. Sikirić et al., “Novel Cytoprotective Mediator, Stable Gastric Pentadecapeptide BPC 157: Vascular Recruitment and Gastrointestinal Tract Healing,” Curr. Pharm. Des., vol. 24, no. 18, pp. 1990–2001, 2018. 
• S. Seiwerth et al., “BPC 157 and Standard Angiogenic Growth Factors: Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing,” Curr. Pharm. Des., vol. 24, no. 18, pp. 1972–1989, 2018. 
• C.-H. Chang et al., “The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration,” J. Appl. Physiol., vol. 110, no. 3, pp. 774–780, Oct. 2010. 
• Y.-L. Hu et al., “FAK and paxillin dynamics at focal adhesions in the protrusions of migrating cells,” Sci. Rep., vol. 4, p. 6024, Aug. 2014. 
• K. Skrlec et al., “Engineering recombinant Lactococcus lactis as a delivery vehicle for BPC-157 peptide with antioxidant activities,” Appl. Microbiol. Biotechnol., vol. 102, no. 23, pp. 10103–10117, Dec. 2018. 
• D. Strinic et al., “BPC 157 counteracts QTc prolongation induced by haloperidol, fluphenazine, clozapine, olanzapine, quetiapine, sulpiride, and metoclopramide in rats,” Life Sci., vol. 186, pp. 66–79, Oct. 2017. 
• N. Jelovac et al., “Pentadecapeptide BPC 157 attenuates disturbances induced by neuroleptics: effect on catalepsy and gastric ulcers in mice and rats,” Eur. J. Pharmacol., vol. 379, no. 1, pp. 19–31, Aug. 1999. 
• J. Tlak Gajger et al., “Stable gastric pentadecapeptide BPC 157 in honeybee (Apis mellifera) therapy to control Nosema ceranae invasions in apiary conditions,” J. Vet. Pharmacol. Ther., vol. 41, no. 4, pp. 614–621, Aug. 2018.